Our News

Our companies and we are trying to stay at forefront of innovation with the goal to save and improve patients' lives. We are glad to share our progress on the way to achieving this goal.

June 2020

BB Pureos Bioventures expands its advisory board by appointing Dr. Omar Khwaja

June 2020

With Roivant Sciences another partner has joined BaseLaunch Phase II

June 2020

BB Pureos Bioventures joins BaseLaunch Phase II as the first venture capital fund

May 2020

"Das Coronavirus wird in der Zivilisation bleiben." Interview mit Klaus Breiner in der Engadiner Post.

April 2020

BB Pureos Bioventures expands its team of Partners and Entrepreneurs with the appointment of Dr. Anja Harmeier

January 2020

Eyevensys Closes USD 30 mn Series B Financing

July 2019

AM-Pharma raises EUR 116 mn to conduct pivotal Phase III Trial of recAP in Acute Kidney Injury

April 2019

BB Pureos Bioventures (Pureos) co-led a CHF 12.5 mn investment in Alentis Therapeutics AG

March 2019

NovaGo Therapeutics raises CHF 10 mn to develop regenerative anti-Nogo therapy for stroke

June 2018

Hochkarätiger Beirat für neue Risikokapitalgesellschaft BB Pureos Bioventures

May 2018

NZZ.ch - Fünf Fragen an Dominik Escher

April 2018

NZZ.ch - Im Biotech-Sektor klafft eine Finanzierungslücke

February 2018

Agéfi - Pureos Bioventures se focalise sur les biotechs actives dans la recherche de médicaments

February 2018

Initative for venture capital in Switzerland